8-K: Cognition Therapeutics Announces Year-End 2024 Financial Results and Provides Business Update

Cognition Therapeutics reports positive Phase 2 results for Zervimesine in Dementia with Lewy Bodies (DLB) and Alzheimer's Disease, shifting focus to late-stage trials and extending cash runway into Q4 2025.

Summary

• Cognition Therapeutics announced its financial results for the year ended December 31, 2024, and provided a business update on March 20, 2025.
• The company is focusing on advancing Zervimesine into late-stage trials for DLB and Alzheimer's disease.
• Enrollment in the Phase 2 dry AMD clinical study was concluded to allocate resources to planned registrational programs for Alzheimer's and DLB.
• The company plans to request separate end-of-Phase 2 meetings with the FDA for Alzheimer's disease and DLB in early second quarter of 2025.
• Cash and cash equivalents as of December 31, 2024, were approximately $25.0 million, with $50.0 million in obligated grant funds remaining from the NIA.
• The company reported a net loss of $34.0 million, or $(0.86) per basic and diluted share for the year ended December 31, 2024, compared to a net loss of $25.8 million, or $(0.86) per basic and diluted share for 2023.

Sentiment

Score: 7

Explanation: The document presents positive clinical trial results and a clear path forward, but the net loss and need for additional funding temper the overall sentiment.

Positives

• Positive Phase 2 results for Zervimesine in DLB and Alzheimer's disease.
• The company is advancing Zervimesine into late-stage trials for DLB and Alzheimer's disease.
• The company has $25.0 million in cash and cash equivalents as of December 31, 2024, and $50.0 million in obligated grant funds remaining from the NIA.
• Development of a novel chemical process for the manufacture of Zervimesine as part of the Company's Phase 3 readiness plan.

Negatives

• The company reported a net loss of $34.0 million for the year ended December 31, 2024.
• The company concluded enrollment in the Phase 2 dry AMD clinical study to devote resources to planned registrational programs for Alzheimer's and DLB.

Risks

• The company's ability to secure new (and retain existing) grant funding.
• The company's ability to successfully advance its current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto.
• Uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials.
• The timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates.

Future Outlook

The company plans to meet with the FDA on plans to start Phase 3 studies in Alzheimer's disease and DLB and is actively evaluating options to fund clinical trials, including potential partnering opportunities with pharmaceutical companies.

Management Comments

• Zervimesine delivered positive clinical data during 2024 from two key Phase 2 studies: the SHIMMER study in DLB and the SHINE study in Alzheimer's disease.
• These results show the value that zervimesine holds as we advance towards Phase 3 clinical trials.
• Looking ahead, we will meet with the FDA on plans to start Phase 3 studies in Alzheimer's disease and DLB.
• In parallel, we are actively evaluating options to fund our clinical trials, including potential partnering opportunities with pharmaceutical companies.

Industry Context

Cognition Therapeutics is focusing on neurodegenerative disorders, a field with significant unmet medical need and growing interest from pharmaceutical companies. The positive Phase 2 results position them competitively as they seek partnerships and funding for Phase 3 trials.

Comparison to Industry Standards

• The reported 91% slowing of cognitive decline in the SHIMMER study for DLB is a significant result compared to other treatments in development, such as those from Denali Therapeutics and Biohaven Pharmaceuticals, which are also targeting neurodegenerative diseases.
• The near-total preservation of cognition in a subgroup of Alzheimer's patients in the SHINE study is notable when compared to the modest improvements seen with drugs like Aduhelm from Biogen and Eisai, highlighting the potential of Zervimesine in specific patient populations.
• The company's cash runway extending into Q4 2025 is comparable to other clinical-stage biotech companies like Anavex Life Sciences and Cassava Sciences, which are also focused on Alzheimer's disease and are actively managing their resources to advance their clinical programs.

Stakeholder Impact

• Shareholders: Positive clinical trial results could increase shareholder value.
• Employees: Focus on Alzheimer's and DLB programs may impact job security.
• Patients: Potential for new treatment options for Alzheimer's and DLB.

Next Steps

• End-of-Phase 2 meetings with the FDA to align on plans for Phase 3 clinical protocols for both Alzheimer's disease and DLB.
• Actively evaluating options to fund clinical trials, including potential partnering opportunities with pharmaceutical companies.
• Advancing Zervimesine into late-stage trials for DLB and Alzheimer's disease.

Key Dates

Keywords

Zervimesine, Cognition Therapeutics, Alzheimer's disease, Dementia with Lewy Bodies, DLB, Clinical trials, Financial results, CT1812